药理干预治疗肝硬化:从挑战到新兴的治疗视野
Yuan Gao1, Xin Liu2, Yunyi Gao3
1Fourth Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Gut and liver
|August 29, 2024
概括
肝硬化炎的管理是具有挑战性的. 针对氨酸- ангиотензин- 阿尔多素系统 (RAAS) 的新疗法显示出改善患者结果和生存的希望.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 是不补偿性肝硬化的常见并发症,严重影响患者的生活质量和存活率.
- 目前的治疗方法,如利尿剂提供症状缓解,但对生存的影响有限.
- 了解炎病理生理学是有效管理的关键.
研究的目的:
- 为了审查肝硬化炎的发病因子.
- 讨论当前药理疗法的挑战.
- 探索针对氨酸- ангиотензин- 阿尔多素系统 (RAAS) 的新兴疗法.
主要方法:
- 文献综述专注于肝硬化.
- 分析氨酸- ангиотензин- алдостерон系统 (RAAS) 在炎形成中的作用.
- 评估当前和新的治疗策略.
主要成果:
- 氨酸- ангиотензин- алдостерон系统 (RAAS) 通过损害和水分泌,在肝硬化发育中发挥着关键作用.
- 现有的治疗方法在改善存活率方面面临局限性.
- 针对性RAAS调制为炎治疗提供了潜在的新途径.
结论:
- 氨酸- ангиотензин- алдостерон系统 (RAAS) 是肝硬化的关键因素.
- 针对RAAS的新型药物有可能提高治疗疗效和患者存活率.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
122
Esophageal Varices-II: Clinical Features and Management
57
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
57
Pleural Effusion II: Symptoms and Management
158
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
158
Chronic Pancreatitis II: Collaborative Care
77
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
77
Drugs for Treatment of Constipation-Predominant IBS
146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153


